1H-4(5)-cyclo-substituted imidazole derivatives as histamine H.sub.3 receptor agents
US6072057A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Feb 11, 1998 |
| Grant date | Jun 6, 2000 |
| Priority date | — |
| Expiry date | Feb 11, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to 1H-4(5)-substituted imidazole derivates of formula (I), wherein A is (a); (b); or (c) ##STR1## wherein R.sub.1 is lower alkyl or lower alkoxy; PA1 R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.7 and R.sub.8 are each independently hydrogen or lower alkyl; PA1 R.sub.6 is hydrogen, lower alkyl or lower alkoxy and R.sub.5 and R.sub.6 can be joined to form a 4, 5 or 6 membered ring. The compounds of formula (I) have H.sub.3 histamine receptor agonist activity. The pharmaceutically acceptable salts, and individual stereoisomers of compounds of formula (I) above, as well as mixtures thereof, are also contemplated as falling within the scope of the present invention. The present invention also provides pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with an effective amount of a compound of formula (1). The present invention also provides a method of treating conditions in which activation of histamine H.sub.3 receptors may be of therapeutic importance such as allergy, inflammation, cardio or cerebrovascular disease, gastrointestinal disorders and CNS disorders involving psychiatric disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.